The biotech firm reports a Q1 GAAP loss of $526.11 per share while holding $388.9 million in cash through March 31, 2026.
BridgeBio Oncology Therapeutics reported a first-quarter GAAP loss of $526.11 per share, reflecting ongoing investment in drug development. The company’s cash position remained strong, with $388.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
The cash reserve is projected to extend the company’s runway into 2028, providing financial flexibility for clinical programs. No prior quarterly earnings were provided for comparison, as the firm focuses on early-stage oncology therapies.
Market reaction was not disclosed in the release.